not necessarily indicative of any AV fund or investor
If GI side effects are manageable, add cagrilintide at 0.25 mg weekly starting in week 5, while simultaneously increasing retatrutide to 2 mg as per its standard titration
McAuley K, Hopkins C, Smith K, McLay R, Williams S, Taylor R, Mann J
Krishnan A, Sims OT, Surapaneni PK, Woreta TA, Alqahtani SA (2023) Risk of adverse cardiovascular outcomes among persons living with HIV and nonalcoholic fatty liver disease: a multicenter matched cohort study
It also includes targeted supplements like GLP-1 Daily Support and Weight Loss Boost to address nutritional needs during the weight loss process
Further comparative studies with PAP therapy are also warranted to establish optimal treatment strategies and better define patient selection criteria